





SDRAB Meeting Workshop Report: Sleep in a Bottle?: Research needs and gaps in ingested, non-prescription strategies for healthy sleep Workshop dates: September 15, 16, 2025

Barbara C. Sorkin, PhD

December 4, 2025

Co-Director, NIH Consortium Advancing Research on Botanical and Other Natural Products



Acknowledgements

NIH Co-Organizers

Barbara C. Sorkin Maria Canino Shilpy Dixit

External Co-Chairs

Michael Grandner Eva Schernhammer

Logistics and Planning

Ashley Cornett Katy Fuller James Hubley

WRAIR

Tracy Jill Doty Emily Lowery-Gionta

NASEM

Claire Stroud Alex Helman Sheena Posey Norris

ODS Colleagues

Andrew Bremer Stephanie George Paul Coates Laura Dwyer Johanna Dwyer Jaime Gahche Adam Kuszak Sarah Marshall Stefan Pasiakos Edwina Wambogo

NIH Colleagues

Marishka Brown
Todd Horowitz
Dan Raiten
Dana Schloesser
Steve Tsang
Inna Belfer
Sekai Chideya-Chihota
Preetha Abraham

Raffy Gorospe
Janet He
Karen Huss
Shailesh Kumar
Danny Lewin
Yuan Luo
Sunila Nair
Jia Bei Wang
Dan Xi



Research Letter

2023 Apr 25;329(16):1401-1402.

doi: 10.1001/jama.2023.2296

Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US

Pieter A. Cohen, MD¹; Bharathi Avula, PhD²; Yan-Hong Wang, PhD²; Kumar Katragunta, PhD²; Ikhlas Khan, PhD²

"Prior to the COVID-19 pandemic, melatonin was used by an estimated 1.3% of children in the US, most commonly for sleep, stress, and relaxation.^{1,2} Despite the lack of high-quality evidence to support melatonin's efficacy for these indications in healthy children, use increased during the COVID-19 pandemic.

Calls for pediatric melatonin ingestions to US Poison Control Centers increased 530% from 2012 to 2021 and were associated with 27,795 emergency department and clinic visits, 4,097 hospitalizations, 287 intensive care unit admissions, and 2 deaths.3"

Why focus on ingestibles when CBTi works?

- 1 in 5 US adults use either prescription or OTC sleep aids
- In the 2002 NHIS 64.8% of people who reported insomnia or trouble sleeping used "biologically-based approaches" (mostly ingested products such as herbs, nutritional products)
- Nutrition Business Journal reports strong sales of DS for "Sleep Health" (> for brain health or healthy aging, < for weight loss)
- Over 2% (nearly 2700) products in ODS' DSLD are labeled for sleep use
- What are these products? Are they safe? Effective?

DS in DSLD with "sleep" on the label

Total number of on-market sleep advertised products: **2,685**

- Melatonin: 1,402 (52%)
- Magnesium: 577 (21%)
- GABA: 360 (13%)
- Botanical ingredients:
 - # of ingredients that appear in ≥ 100 products: 8
 - # of ingredients that appear in 50-99 products: 10
 - # of ingredients that appear in 10-49 products: 50
 - # of ingredients that appear in 5-9 products: 39
 - # of ingredients that appear in 2-4 products: 98
 - # of ingredients that appear in 1 product: 74



4 products	3 products	2 products		1 product		
Buckthorn Camphene Capsicum annuum Chokeberry Corydalis Cynanchum wilfordii Eucalyptus Garcinia cambogia Garlic Guggul Horsetail Indian gooseberry Ligusticum wallichii Longjack Motherwort Noni Oat milky seed Phlomis umbrosa Sceletium tortuosum White willow	Anise Apocynum venetum Arrhenatherum Black elder Blessed thistle Cascara sagrada Ceramosides Chaga Citronellol Cutch tree bark Devil's claw Epimedium koreanum Eucommia ulmoides tree Grassleaf sweetflag Gymnema Honeysuckle Horse chestnut Lemon verbena Lobelia Marshmallow Oriental arbor-vitae Pasque flower Platycodon grandiflorus Poppy Pygeum Safflower Shilajit Soursop Stinging nettle Wild yam Zea mays	Agaricus Amber resin Amla berry Aronia Aster alpigenus Atractylodes Barberry Basil Bayberry Black root Bladderwrack Blue malva flower Ceratonia siliqua pod Chicory Cnidium monnieri Codonopsis Coptis Coriander Crocus sativus Dwarf morning glory Eclipta Eurycoma longifolia Ficus benghalensis Finger-leaf morning glory Forskolin Forsythia Guarana Guggulipid Hibiscus Horehound Horny goat weed Horseradish	Indian tinospora Isatis Long pepper Montmorency cherry Mugwort Nelumbo nucifera Nettle Nutmeg Phragmites Pumpkin seed Sage Salvia sclarea Siberian rhodiola Slippery elm Thyme Wheat grass	Achillea millefolium Acorus calamus Albizia julibrissin durazz Barley malt Biota Bitter blocker Black nightshade Blue lotus Bupleurum Caraway Chebulic myrobalan Christmas rose Cissus quadrangularis Citicoline Costus Cumin Dodder seed Dwarf lilyturf English hawthorn Feverfew Fig tree Figworts Gentian Goldenseal Grapevine Gum resin Huperzia serrata Hyssop Indian jalap Indian sarsaparilla Jamaica dogwood Kratom	Lemon myrtle Logan Longan Luo han guo Maca Madagascar vanilla extract Maritime pine bark Millet Mistletoe Muira puama Mulungu bark Mung bean Mustard seed Nigella sativa Olea europaea Ophiopogon Paeonia lactiflora Paprika Partridgeberry Phytosterol Picrorhiza kurroa Red root Rheum palmatum Rooibos Rose hip Safed musli Sandalwood Sesame Sheep sorrel Sophora japonica l. South african	Geranium root Spikenard Suan zao ren Szechuan lovage root Tilia tomentosa Tremella fuciformis Tripterygium wilfordii Vidanga Woad Wuhan tonify wei qi tang Yacon syrup

Workshop Agenda: Day 1

- Scope of the Problem: Prevalence, Causes, and Consequences of Poor Sleep Health
 - Dan Buysse, Orfeu Buxton, Aric Prather
- Ashwagandha to Zinc and Outside the Bottle: Strategies People Use to Improve Sleep
 - Michael Grandner, Michael Heinrich, Todd Arnedt, Christopher Scott Colwell, Mary Paine
- Melatonin mini-session
 - Judith Owens, Jeanne Duffy
- Lightning product proposals
 - Chengguo Xing (kava kava), J. Kent Werner (magnesium)
- Overview of Mediators, Mechanisms and Targets for Sleep Interventions
 - Philip Cheng, William Wisden, Jason Gerstner, Dragana Rogulja

Link to Agenda

Workshop Agenda: Day 2

- Epidemiological, Nutritional and Ethnobotanical: Exploring Application of 21st Century Methods and Traditional Uses to Query Gaps in Knowledge of Potential Sleep Remedies
 - Ina Vandebroek, C. Benjamin Naman, Steve Tsang, Jeran Stratford, Angus Burns
- Relevant Clinical Datasets
 - NHANES, MHANES, Nutrition for Precision Health, ECHO, ABCD study
- Preclinical Approaches: Exploring Application of New Approach Models to Gaps in Knowledge of Over-the-Counter Products Used for Sleep
 - Yitong Liu, Alysson Muotri, Roger Linington, Doris Kretzschmar
- Approaches to Accelerate Learning from Clinical Trials
 - Chris Coffey, Miguel Hernán, Jeff Chen

Link to Agenda

Workshop Stats

Day 1

- 452 attendees
- 16 presenters

Day 2

- 327 attendees
- 18 presenters

Needs and gaps

Sleep in a Bottle?:

Research needs and gaps in ingested, nonprescription strategies for healthy sleep

Research needs - overall

- Objective measures of sleep sufficiency replicable, validated, preferably scalable (portable, inexpensive)
- Include both objective/quantitative AND subjective/PROs in clinical trials
- Longitudinal studies and trials
- Inclusion of participants across the lifespan and other subpopulations (e.g., pregnancy)
- More study of wearables: validation, standardization, harmonization, raw data and processing algorithms should be FAIR
- Validated approaches to combine sleep and dietary intake data from large data sets to explore for associations

General, Major Gaps

- Epidemiological data what OTC products are people using for sleep?
- Replicated data on safety, sleep effects of natural products including effects of Cannabis products on sleep
- Generally little rigorous data on potential mechanisms of botanicals, including evidence re active compounds, targets, biological/behavioral effects, dose-response, ADME, PK, potential for drug and/or food interactions
- Product integrity chemistry to control for efficacy, bioavailability, safety, monitoring for contaminants and adulterants – about 1/3 of lavender products adulterated in recent study (Jalil & Heinrich, Eur J Pharm Sci 2025)
- Higher throughput approaches to screen ingested products for likelihood of sleep activity in silico, organoid, model organisms, esp. Drosophila

Gaps and needs: Alcohol

Gap: There is a lack of studies with objective sleep outcomes

Use for sleep has increased significantly in the past 20 years Common, but used less often than Cannabis and other natural products or OTC medicines

Research needs:

- Longitudinal studies w/ objective (& PR) outcomes, effective placebo (or other) controls and checks on control credibility
- Studies of long-term effects

Gaps and needs: Cannabis

47% of US adults using medicinal Cannabis report having insomnia

Research gap:

Rigorous clinical trials with effectively blinded controls, chemically well-characterized product, objective as well as PR sleep outcomes

Research need:

As above, with dose, circadian timing and route of administration optimized

Gaps and needs: Kratom (Mitragyna speciosa)

- Increased use in US from 3-5 million in 2016 to 11-15 million users in early 2023.
 - Commonly used for chronic pain, opiate addiction
- Interacts with α-adrenergic, dopaminergic, and serotoninergic receptors as well as opioid receptors
 - Stimulant at low doses; possible "opioid sparing agent" at higher doses
- No serious AEs but risk of drug interactions
 - Exploration of addiction-related effects

Research need: RCT of existing well-characterized products with dose-ranging, objective outcomes for sleep, PRO for sleep and pain





Gaps and needs: Melatonin

Jeanne Duffy, Brigham and Women's Hospital and Judith Owens, Harvard Medical School


Most commonly used in US, often combined with other ingredients: 20% of children received melatonin from parents in last month in 2024 survey, half of these without healthcare provider recommendation


- Strong evidence for circadian shifts (e.g., jet lag, shift work)
- Negligible differences in adults taking 0.3 vs. 5.0 mg doses

Research gaps:

- Effects on sleep maintenance, wake after sleep onset, sleep duration, sleep efficiency: these are not well documented
- Effects of long-term use
- RCTs in children with insomnia, neurodevelopmental disorders, medical and psychiatric comorbidities with comparators
- Dose response data
- Treatment combination studies

Practitioner need: clear, evidence-based guidelines for pediatric providers





Higher throughput translational models with potential to screen interventions for potential efficacy, target engagement

Day 2, Session 2: Yitong Liu (FDA), Alysson Muotri (University of California), Roger Linington (Simon Fraser University)

Goals: Screening for relevant active compounds to support reproducibility, bioavailability, safety, PK/PD, drug interactions

NAM and in silico models


- Biological and toxicological pathways and mechanisms of action for isolated botanicals, but cannot currently model synergistic interactions
- NP Analyst to predict which compounds have which biological activities. The method is chemistry- and mechanism-agnostic and can be applied to any model.
- Cortical organoids: can include multiple neuronal cell types as well as glia, show oscillations in melatonin and cortisol

Approaches to Accelerate Learning from Clinical Trials

Day 2, Session 3: Chris Coffey (University of Iowa), Miguel Hernán (Harvard), Jeff Chen (Radicle Science)

 Clinical trials are large, expensive, and time-consuming

- Adaptive designs offer flexibility
 - Master protocol for multiple interventions or subtypes
 - Platform trials to evaluate multiple therapies and/or subpopulations
- Target trial emulation
- Decentralized trials



Pallmann et al (2018), BMC Medicine, 16(1):29.



Thank you! Contact us:

https://ods.od.nih.gov/About/Contact_Us.aspx

Barbara C. Sorkin, Ph.D.
Co-Director, Botanical Research
Centers Program
Office of Dietary Supplements
National Institutes of Health

Barbara.Sorkin@nih.gov



Non-mammalian models to study sleep

Doris Kretzschmar (Oregon Health & Science University)

Zebrafish

- Actigram and electrophysiological activity
- Sleep waves that resemble human REM- and NREM-like activity
- Same neurotransmitters as humans
- Problems: aquatic environment; gene duplication

Drosophila

- Video tracking
- Similar sleep fragmentation and total sleep time